---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066396"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:20:51.419907+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Dyne Q1 net loss $115.4M ($1.05/sh); advances DM1 & DMD toward 2026-2027 approvals

## Summary
- Cash $677.5M; expects funding operations into H2 2026.
- R&D expenses $106.4M (Q1 2025) vs $44.5M (Q1 2024); net loss widened.
- ACHIEVE Registrational Expansion Cohort for DYNE-101 (DM1) initiated; up to 48 patients; data H1 2026.
- DELIVER Registrational Expansion Cohort for DYNE-251 (DMD) fully enrolled (32 patients); data late 2025.
- New CFO (Erick Lucera), CBO (Vikram Ranade), CSO (Ranjan Batra); Oxana Beskrovnaya named CIO.

## SEC filing metadata
- accession: 0000950170-25-066396
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000095017025066396/0000950170-25-066396-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000095017025066396/dyn-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066396
- JSON: https://secwatch.observer/filing/0000950170-25-066396.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066396.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.